COGT (Cogent Biosciences) Moat Score: 3/10 (As of Jun. 28, 2026)


COGT Cogent Biosciences Inc COGT
25 GF Score
Price $38.05
! 5 Warning Signs
View Full Analysis

What is Cogent Biosciences Moat Score?

Cogent Biosciences COGT +0.26% 25 Moat Score is 3 as of Jun. 28, 2026. GuruFocus rates COGT with a GF Score™ of 25/100. The stock has 5 warning signs investors should review. Among 1,402 Biotechnology companies, Cogent Biosciences ranks better than 75.46% on this metric.

Cogent Biosciences has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Cogent Biosciences has No Moat: Cogent Biosciences is in the biotech sector with limited market share and no significant intellectual property or patents. It lacks strong brand strength, customer loyalty, and regulatory barriers. The company is in a competitive field with transient advantages and no clear cost leadership.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cogent Biosciences might have No Moat - Very weak/transient advantages.

Cogent Biosciences  (NAS:COGT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cogent Biosciences Moat Score Related Terms

COGT vs SRRK, RYTM, PTCT: Moat Score Comparison

For the Biotechnology subindustry, Cogent Biosciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cogent Biosciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cogent Biosciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Cogent Biosciences's Moat Score falls into.


COGT
25GF Score
Cogent Biosciences Inc COGT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Cogent Biosciences (COGT) has a Moat Score of 3 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Cogent Biosciences ranks #344 out of 1402 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Cogent Biosciences' Moat Score too high?
Cogent Biosciences' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Cogent Biosciences' value of 3 is 50% above this industry median. Based on the distribution chart, Cogent Biosciences ranks #344 out of 1402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cogent Biosciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' Moat Score compare to SRRK and RYTM?
According to the Biotechnology industry distribution chart, Cogent Biosciences ranks #344 out of 1402 companies for Moat Score. This places Cogent Biosciences in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Cogent Biosciences' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cogent Biosciences's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogent Biosciences's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Cogent Biosciences' overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current Moat Score is 3 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cogent Biosciences Business Description

Address 275 Wyman Street, 3rd Floor, Waltham, MA, USA, 02451
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
25GF Score

Get the complete analysis for COGT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.05
Price